Sandra Rodriguez-Perales

Dr. Sandra Rodriguez-Perales

Sandra RodríguMolecular Cytogenetics Unit Centro Nacional Investigaciones Oncológicas (CNIO) C/ Melchor Fernández Almagro,3 28029, Madrid, Spain
orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2022 in Gut
Verified
Journal Article
Open access
PDF file
EKEce Kartal
Ece Kartal
TSThomas S B Schmidt
Thomas S B Schmidt
EMEsther Molina-Montes
Esther Molina-Montes
SRSandra Rodriguez-Perales
Sandra Rodriguez-Perales
JWJakob Wirbel
Jakob Wirbel
PBPeer Bork
Peer Bork
Background Recent evidence suggests a role for the microbiome in pancreatic ductal adenocarcinoma (PDAC) aetiology and progression. Objective To explore the faecal and salivary microbiota as potential diagnostic biomarkers. Methods We applied shotgun metagenomic and 16S rRNA amplicon sequencing to samples from a Spanish case–control study (n=136), including 57 cases, 50 controls, and 29 patients with chronic pancreatitis in the discovery phase, and from a German case–control study (n=76), in the validation phase. Results Faecal metagenomic classifiers performed much better than saliva-based classifiers and identified patients with PDAC with an accuracy of up to 0.84 area under the receiver operating characteristic curve (AUROC) based on a set of 27 microbial species, with consistent accuracy across early and late disease stages. Performance further improved to up to 0.94 AUROC when we combined our microbiome-based predictions with serum levels of carbohydrate antigen (CA) 19–9, the only current non-invasive, Food and Drug Administration approved, low specificity PDAC diagnostic biomarker. Furthermore, a microbiota-based classification model confined to PDAC-enriched species was highly disease-specific when validated against 25 publicly available metagenomic study populations for various health conditions (n=5792). Both microbiome-based models had a high prediction accuracy on a German validation population (n=76). Several faecal PDAC marker species were detectable in pancreatic tumour and non-tumour tissue using 16S rRNA sequencing and fluorescence in situ hybridisation. Conclusion Taken together, our results indicate that non-invasive, robust and specific faecal microbiota-based screening for the early detection of PDAC is feasible.

3 June 2014 in Nature Communications
Verified
Journal Article
Closed access
PDF file
RTRaul Torres-Ruiz
Raul Torres-Ruiz
MMM. C. Martin
M. C. Martin
AGA. Garcia
A. Garcia
JCJuan C. Cigudosa
Juan C. Cigudosa
JRJ. C. Ramirez
J. C. Ramirez
SRSandra Rodriguez-Perales
Sandra Rodriguez-Perales

4 August 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
BOBarbara Oldrini
Barbara Oldrini
NVNuria Vaquero-Siguero
Nuria Vaquero-Siguero
QMQuanhua Mu
Quanhua Mu
PKPaula Kroon
Paula Kroon
YZYing Zhang
Ying Zhang
MSMassimo Squatrito
Massimo Squatrito
Temozolomide (TMZ) is an oral alkylating agent used for the treatment of glioblastoma and is now becoming a chemotherapeutic option in patients diagnosed with high-risk low-grade gliomas. The O-6-methylguanine-DNA methyltransferase (MGMT) is responsible for the direct repair of the main TMZ-induced toxic DNA adduct, the O6-Methylguanine lesion. MGMT promoter hypermethylation is currently the only known biomarker for TMZ response in glioblastoma patients. Here we show that a subset of recurrent gliomas carries MGMT genomic rearrangements that lead to MGMT overexpression, independently from changes in its promoter methylation. By leveraging the CRISPR/Cas9 technology we generated some of these MGMT rearrangements in glioma cells and demonstrated that the MGMT genomic rearrangements contribute to TMZ resistance both in vitro and in vivo. Lastly, we showed that such fusions can be detected in tumor-derived exosomes and could potentially represent an early detection marker of tumor recurrence in a subset of patients treated with TMZ.

25 November 2021 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
Susana Garcia-SilvaSusana Garcia-Silva
Susana Garcia-Silva
ABAlberto Benito-Martín
Alberto Benito-Martín
LNLaura Nogués
Laura Nogués
AHAlberto Hernández-Barranco
Alberto Hernández-Barranco
MMMarina S. Mazariegos
Marina S. Mazariegos
Hector PeinadoHector Peinado
Hector Peinado

1 May 2002 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
SESilvia Espejel
Silvia Espejel
SFSonia Franco
Sonia Franco
SRSandra Rodriguez-Perales
Sandra Rodriguez-Perales
SBSimon D. Bouffler
Simon D. Bouffler
JCJuan C. Cigudosa
Juan C. Cigudosa
MBMaría A. Blasco
María A. Blasco
Here we analyze the functional interaction between Ku86 and telomerase at the mammalian telomere by studying mice deficient for both proteins. We show that absence of Ku86 prevents the end‐to‐end chromosomal fusions that result from critical telomere shortening in telomerase‐deficient mice. In addition, Ku86 deficiency rescues the male early germ cell apoptosis triggered by short telomeres in these mice. Together, these findings define a role for Ku86 in mediating chromosomal instability and apoptosis triggered by short telomeres. In addition, we show here that Ku86 deficiency results in telomerase‐dependent telomere elongation and in the fusion of random pairs of chromosomes in telomerase‐proficient cells, suggesting a model in which Ku86 keeps normal‐length telomeres less accessible to telomerase‐ mediated telomere lengthening and to DNA repair activities.

25 September 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
OCOriol Calvete
Oriol Calvete
PMPaula Martinez
Paula Martinez
PGPablo Garcia-Pavia
Pablo Garcia-Pavia
CBCarlos Benitez-Buelga
Carlos Benitez-Buelga
BPBeatriz Paumard-Hernández
Beatriz Paumard-Hernández
JBJavier Benítez
Javier Benítez
Cardiac angiosarcoma (CAS) is a rare malignant tumour whose genetic basis is unknown. Here we show, by whole-exome sequencing of a TP53-negative Li–Fraumeni-like (LFL) family including CAS cases, that a missense variant (p.R117C) in POT1 (protection of telomeres 1) gene is responsible for CAS. The same gene alteration is found in two other LFL families with CAS, supporting the causal effect of the identified mutation. We extend the analysis to TP53-negative LFL families with no CAS and find the same mutation in a breast AS family. The mutation is recently found once in 121,324 studied alleles in ExAC server but it is not described in any other database or found in 1,520 Spanish controls. In silico structural analysis suggests how the mutation disrupts POT1 structure. Functional and in vitro studies demonstrate that carriers of the mutation show reduced telomere-bound POT1 levels, abnormally long telomeres and increased telomere fragility.